Comparison of Zymeworks Inc. (ZYME) and argenx SE (NASDAQ:ARGX)

Zymeworks Inc. (NYSE:ZYME) and argenx SE (NASDAQ:ARGX) compete against each other in the Biotechnology sector. We will contrast them and contrast their profitability, analyst recommendations, risk, dividends, earnings and valuation, institutional ownership.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Zymeworks Inc. 74.17M 6.74 13.10M -0.35 0.00
argenx SE N/A 0.00 N/A -1.73 0.00

Table 1 shows the top-line revenue, earnings per share (EPS) and valuation for Zymeworks Inc. and argenx SE.

Profitability

Table 2 provides the return on equity, net margins and return on assets of the two firms.

Net Margins Return on Equity Return on Assets
Zymeworks Inc. -17.66% -9.2% -8%
argenx SE 0.00% 0% 0%

Insider and Institutional Ownership

Institutional investors held 37.7% of Zymeworks Inc. shares and 58.2% of argenx SE shares. Insiders held 22.1% of Zymeworks Inc. shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Zymeworks Inc. 7.85% -1.56% -4.54% -21.14% 61.77% 82.8%
argenx SE 3.38% 0.14% 13.31% 0.68% 229.08% 58.44%

For the past year Zymeworks Inc. was more bullish than argenx SE.

Summary

On 5 of the 9 factors Zymeworks Inc. beats argenx SE.

Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The companyÂ’s lead product candidate include ZW25, a novel bispecific antibody that is in Phase I clinical trial for the treatment of breast, gastric, and ovarian cancers. It is also developing ZW33, a bispecific anti-human epidermal growth factor receptor 2 antibody-drug conjugate that is in preclinical development stage for the treatment of breast and ovarian cancers. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd., Eli Lilly and Company, Celgene Corporation and Celgene Alpine Investment Co. LLC, GlaxoSmithKline Intellectual Property Development Limited, and Daiichi Sankyo Co., Ltd. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company’s lead clinical stage product candidates include ARGX-113, a product in Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis and immune thrombocytopenia; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of hematological cancers, such as T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome. It is also developing ARGX-111 to treat solid tumors with MET amplification; ARGX-109 for the treatment of rheumatoid arthritis; ARGX-112 to treat skin inflammation; ARGX-115, a cancer immunotherapy-focused product candidate; and ARGX-116 for the treatment of dyslipidemia. The company has license and collaboration agreements with AbbVie S.Á.R.L.; Bird Rock Bio, Inc.; LEO Pharma A/S; Shire International GmbH; and Bayer AG. argenx SE was founded in 2008 and is based in Breda, the Netherlands.